| Walter H Schriefer, MD | |
|
509 Biltmore Ave, Asheville, NC 28801-4601 | |
| (843) 237-3378 | |
| (843) 237-5073 |
| Full Name | Walter H Schriefer |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 35 Years |
| Location | 509 Biltmore Ave, Asheville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639133986 | NPI | - | NPPES |
| 74921 | Other | NC | BCBS |
| 8974921 | Medicaid | NC | |
| 930042438 | Other | NC | RAILROAD |
| Q35504 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 35504 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vidant Chowan Hospital | Edenton, NC | Hospital |
| Vidant Bertie Hospital | Windsor, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vidant Medical Group Llc | 0345343893 | 849 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | Transylvania Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549208 PECOS PAC ID: 4880592427 Enrollment ID: O20031222000135 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | Carolina Mountain Emergency Medicine Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457317620 PECOS PAC ID: 0345223798 Enrollment ID: O20040608001059 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | East Carolina Health-bertie |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578541660 PECOS PAC ID: 1355251661 Enrollment ID: O20041112000143 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | Blue Ridge Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679570840 PECOS PAC ID: 0648181966 Enrollment ID: O20060410000335 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | Angel Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497753651 PECOS PAC ID: 9638253297 Enrollment ID: O20090312000353 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Entity Name | Highlands-cashiers Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851685051 PECOS PAC ID: 6103096433 Enrollment ID: O20110824000544 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Walter H Schriefer, MD Po Box 1856, Pawleys Island, SC 29585-1856 Ph: (843) 237-3378 | Walter H Schriefer, MD 509 Biltmore Ave, Asheville, NC 28801-4601 Ph: (843) 237-3378 |
News Archive
Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.
Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.
In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes.
The Department of Health and Human Services is working on regulations that would allow it to publish additional in-depth health insurance data, including the number of people enrolled in each insurance plan.
› Verified 2 days ago
Vanessa C Peluso, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1100 Tunnel Rd, Asheville, NC 28805 Phone: 828-298-7911 | |
Dr. Elizabeth T Mccarty, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 Patton Ave, Asheville, NC 28806 Phone: 828-620-0876 | |
Terrence W Burt, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 843-237-3378 Fax: 843-237-5073 | |
Cody Russell, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Dominic Fredrick Tutera, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-257-4472 | |
Krystin Thomas, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Christopher Foster, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1948 Fax: 828-213-1950 |